Affordable Access

Publisher Website

The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations.

  • Bellon, N1
  • Hadj-Rabia, S1, 2
  • Moulin, F3
  • Lambe, C4
  • Lezmi, G2, 5
  • Charbit-Henrion, F2, 6
  • Alby, C6
  • Le Saché-de Peufeilhoux, L1
  • Leclerc-Mercier, S7
  • Hadchouel, A2, 5
  • Steffann, J2, 6
  • Hovnanian, A2, 6, 8
  • Lapillonne, A2, 9
  • Bodemer, C1, 2
  • 1 Department of Dermatology, Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Necker-Enfants Malades Hospital (AP-HP), Imagine Institute, Paris, France. , (France)
  • 2 Paris-Centre University, Paris, France. , (France)
  • 3 Department of Paediatric Intensive Care, Necker-Enfants Malades Hospital (AP-HP), Paris, France. , (France)
  • 4 Department of Paediatric Gastroenterology, Hepatology and Nutrition, Necker-Enfants Malades Hospital (AP-HP), Paris, France. , (France)
  • 5 Department of Pneumo-Allergology, Necker-Enfants Malades Hospital (AP-HP), Paris, France. , (France)
  • 6 Department of Genetics, Necker-Enfants Malades Hospital (AP-HP), Paris, France. , (France)
  • 7 Department of Pathology, Necker-Enfants Malades Hospital (AP-HP), Paris, France. , (France)
  • 8 INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France. , (France)
  • 9 Department of Neonatology, Necker-Enfants Malades Hospital (AP-HP), Paris, France. , (France)
Published Article
British Journal of Dermatology
Wiley (Blackwell Publishing)
Publication Date
Mar 01, 2021
DOI: 10.1111/bjd.19265
PMID: 32479644


Netherton syndrome (NS) is a rare disease caused by SPINK5 mutations, featuring variable skin and hair involvement and, in many cases, allergic manifestations with a risk of lethality, particularly in infants. The clinical management of NS is challenging. To analyse the clinical manifestations of a cohort of infants with NS managed in a reference centre and to draw up recommendations for management. We conducted a monocentric analysis of patients with NS. The inclusion criteria were management in our reference centre, a histologically or molecularly confirmed diagnosis of NS and available epidemiological, clinical and laboratory data. A total of 43 patients with NS were included. Hypernatraemia was reported in 23 cases (54%) and associated with a greater likelihood of enteral and/or parenteral nutritional support (P < 0.001). Moreover, hypernatraemia was more frequent in patients with skin manifestations at birth (P = 0.026) and in patients bearing the c.153delT mutation in SPINK5 exon 3 (P = 0.014). The need for enteral and/or parenteral nutritional support was associated with a history of hypernatraemic dehydration (P < 0.001). Several unexpected extracutaneous complications were recorded, and new mutations were reported. The death rate (9% overall) was higher among the subset of patients bearing the c.153delT deletion. Our data emphasize that neonatal NS is a severe and sometimes lethal multisystem disorder. Patients have a high risk of variable metabolic anomalies (i.e. lethal hypernatraemia) and therefore have major nutritional needs. Cases of NS associated with c.153delT are particularly severe. Unexpected clinical manifestations broadened the phenotypic spectrum of NS. We provide recommendations on the management of the life-threatening manifestations of NS in neonates based on our multidisciplinary experience. © 2020 British Association of Dermatologists.

Report this publication


Seen <100 times